title: Association of MMP-2 expression and prognosis in osteosarcoma patients.
abstract: OBJECTIVE
  Our aim was to investigate the MMP-2 expression and its prognostic value in osteosarcoma patients.
  
  
  METHODS
  We performed RT-qPCR to detect the expression of MMP-2 in 45 paired osteosarcoma tissues and adjacent noncancerous tissues. Immunohistochemical staining assay was used to verify the expression of MMP-2 protein in osteosarcoma patients. Independent-sample T test was used to analyze the difference of MMP-2 expression level between osteosarcoma and control groups. The relationship between clinicopathologic factors and MMP-2 expression was analyzed by chi-square test. Kaplan-Meier was performed to analyze the association of MMP-2 expression and overall survival rate. The prognostic value of clinicopathologic factors and MMP-2 was estimated via Cox regression analysis.
  
  
  RESULTS
  RT-qPCR revealed that the expression of MMP-2 was up-regulated in osteosarcoma group compared with the control group. Besides MMP-2 expression was influenced by pulmonary metastasis (P<0.05) while gender, age, tumor site and Enneking stage showed no obvious impact (P>0.05). Kaplan-Meier curve revealed that patients with positive MMP-2 expression had a shorter survival time than those with negative MMP-2 expression, and the survival rates were 18.5% (5/27) and 44.4% (8/18), respectively. Cox regression analysis indicated that pulmonary metastasis and expression of MMP-2 gene were important factors in the prognosis of osteosarcoma.
  
  
  CONCLUSIONS
  The expression of MMP-2 was associated with pulmonary metastasis, and was related to the prognosis of osteosarcoma. MMP-2 could act as an independent prognostic marker in osteosarcoma patients.
authors.affiliation: Department of Fuxin Central Hospital Fuxin, Liaoning Province, China.
authors.forename: Miao
authors.initials: M
authors.lastname: Zhang
authors.affiliation: Department of Fuxin Central Hospital Fuxin, Liaoning Province, China.
authors.forename: Xuran
authors.initials: X
authors.lastname: Zhang
mesh_terms: D000293:Adolescent; D000328:Adult; D014408:Biomarkers, Tumor / Q000032:analysis*; D001859:Bone Neoplasms / Q000201:enzymology / Q000401:mortality / Q000473:pathology*; D002648:Child; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000096:biosynthesis*; D012516:Osteosarcoma / Q000201:enzymology / Q000401:mortality / Q000473:pathology*; D016133:Polymerase Chain Reaction; D011379:Prognosis; D016016:Proportional Hazards Models; D015854:Up-Regulation; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; C522361:MMP2 protein, human; D020778:Matrix Metalloproteinase 2
keywords: MMP-2; osteosarcoma; prognosis
references.citation: Clin Orthop Relat Res. 2003 Oct;(415):4-18
references.pmid: 14612624
references.citation: Ann Oncol. 2009 Jun;20(6):1136-41
references.pmid: 19153114
references.citation: FEBS Lett. 2013 May 2;587(9):1366-72
references.pmid: 23507142
references.citation: Food Chem Toxicol. 2012 May;50(5):1734-40
references.pmid: 22387266
references.citation: J Clin Oncol. 1991 Oct;9(10):1766-75
references.pmid: 1717666
references.citation: Eur J Surg Oncol. 1998 Dec;24(6):584-600
references.pmid: 9870738
references.citation: Cell. 2001 Dec 14;107(6):789-800
references.pmid: 11747814
references.citation: J Clin Oncol. 1994 Feb;12(2):423-31
references.pmid: 8113851
references.citation: J Clin Oncol. 2002 Feb 1;20(3):776-90
references.pmid: 11821461
references.citation: Clin Orthop Relat Res. 2008 Sep;466(9):2107-13
references.pmid: 18563508
references.citation: Eur J Cancer. 2003 Mar;39(4):488-94
references.pmid: 12751380
references.citation: Ann Oncol. 1998 Aug;9(8):893-9
references.pmid: 9789613
references.citation: J Clin Oncol. 2000 Mar;18(5):1135-49
references.pmid: 10694567
references.citation: Med Pediatr Oncol. 1998 Dec;31(6):471-4
references.pmid: 9835898
references.citation: J Clin Oncol. 2005 Feb 10;23(5):1011-27
references.pmid: 15585754
references.citation: FEBS Lett. 2001 Aug 17;503(2-3):158-62
references.pmid: 11513874
references.citation: Am J Vet Res. 2000 Feb;61(2):111-4
references.pmid: 10685678
references.citation: Int Semin Surg Oncol. 2006 Mar 21;3:7
references.pmid: 16551370
references.citation: Asian Pac J Cancer Prev. 2013;14(6):3681-4
references.pmid: 23886165
references.citation: Vet Pathol. 2003 Jul;40(4):382-94
references.pmid: 12824510
references.citation: Pediatr Clin North Am. 1997 Aug;44(4):973-89
references.pmid: 9286295
references.citation: Int Immunopharmacol. 2015 Jan;24(1):50-8
references.pmid: 25479727
references.citation: J Bone Joint Surg Br. 2002 Jul;84(5):706-11
references.pmid: 12188489
references.citation: J Clin Oncol. 2003 May 15;21(10):2011-8
references.pmid: 12743156
references.citation: Cancer. 2003 Aug 1;98(3):581-9
references.pmid: 12879476
references.citation: Nat Rev Cancer. 2002 Mar;2(3):161-74
references.pmid: 11990853
references.citation: Tumour Biol. 2014 Jun;35(6):5159-65
references.pmid: 24481662
references.citation: J Clin Oncol. 1993 Mar;11(3):449-53
references.pmid: 8445419
references.citation: Eur J Cancer. 2005 Sep;41(14):2079-85
references.pmid: 16115755
references.citation: Paediatr Drugs. 2008;10(5):315-27
references.pmid: 18754698
references.citation: Orphanet J Rare Dis. 2007;2:6
references.pmid: 17244349
references.citation: J Clin Oncol. 1994 Sep;12(9):1849-58
references.pmid: 8083708
references.citation: Cancer Res. 2003 Apr 15;63(8):1759-63
references.pmid: 12702558